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Abetterunderstandingofhumanmetabolism anditsrelationshipwithdiseases isanimportanttask
in human systems biology studies. In this paper, we present a high-quality human metabolic
network manually reconstructed by integrating genome annotation information from different
databases and metabolic reaction information from literature. The network contains nearly 3000
metabolic reactions, which were reorganized into about 70 human-speciﬁc metabolic pathways
according to their functional relationships. By analysis of the functional connectivity of the
metabolites in the network, the bow-tie structure, which was found previously by structure
analysis, is reconﬁrmed. Furthermore, the distribution of the disease related genes in the network
suggeststhattheIN(substrates)subsetofthebow-tiestructurehasmoreﬂexibilitythanotherparts.
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Introduction
Many human diseases are caused by or resulted in an
abnormal metabolic state such as the high glucose concentra-
tion in blood of diabetes patients and the high urine amino-
acid level resulted from liver or renal disorders. Metabolic
processes are also heavily involved in xenobiotics degradation
anddrugclearance(Lewis,2003).Drugsafetyisoftenlinkedto
inhibition of metabolic processes (Mogilevskaya et al, 2006).
Detecting the unusual level of certain speciﬁc metabolites in a
patient’s blood or urine has long been established as an
effective method to identify biomarkers for diagnosing
particular diseases (Schwedhelm and Boger, 2003; Schlotter-
beck et al, 2006). Recent rapid developments of advanced
metabolomics technology is opening up new horizons, as
hundreds or even thousands of metabolites can be measured
simultaneously, providing a much more comprehensive
assessment of a patient’s health status (Grifﬁn and Nicholls,
2006;Kell,2006;Wishartetal,2007).However,forabetterand
in-depth understanding of the largeamounts of data generated
from metabolomics, a complete and high-quality human
metabolic network is essential. This network links various
metabolites by enzyme catalyzed reactions and thus allows us
to discover the genetic mechanism, which causes the
abnormalstateofmetabolitesbynetworkanalysis,andfurther
kinetic modelling. Then drugs, which could target on so far
uncharacterised genes/proteins can be developed for disease
treatment.
Although some human metabolic pathways such as
glycolysis and urea cycle has been discovered almost a
hundred years ago and many pathways have been extensively
studied in biomedical journals and textbooks, a complete
whole picture of human metabolic network is still missing.
Especially the recent development of genome technology
requires us to reconstruct the whole network from genome
level to better understand the genetic basis of metabolic
organization and regulation. A preliminary metabolic network
can be computationally reconstructed easily from the gene
annotation information (Ma and Zeng, 2003; Romero et al,
2005; Reed et al, 2006). Actually such computational
reconstructed networks are available from several metabolic
databases such as KEGG and HumanCyc (Kanehisa et al, 2004;
Romero et al, 2005). However, the quality and completeness of
such networks are often not very high. They need to be
carefully investigated and calibrated through the experimental
results reported in literature. This is a very labor-intensive and
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www.molecularsystemsbiology.comtime consuming (somehow endless) manual process. Even for
simple microorganisms such as Escherichia coli and Sacchar-
omyces cerevisiae, the high-quality metabolic networks recon-
struction often take years to ﬁnish (Reed et al, 2003; Duarte
et al, 2004). In contrast to these microorganisms, which can
use only a few substrates such as glucose to synthesis all the
metabolites, human (and other animals) requires many
essential nutrients forgrowth. Moreover, human is a multicell,
multi-tissue organism with complex networks of interactions
between them. The functions of the cells, tissues and organs
are well differentiated and the metabolites are transferred
within the body through the blood circulation system. There-
fore, the human metabolic network is much more complex
than those of microorganisms, and has different structuraland
functional features, which may be representative for higher
organisms, especially animals.
In this paper we report our ongoing work on human
metabolic network reconstruction. We have combined gen-
ome reconstruction with reconstruction based on literature to
obtain a high-quality human metabolic network with more
than 2000 metabolic genes and nearly 3000 metabolic
reactions (referred as EHMN: Edinburgh Human Metabolic
Network, in the following sections). It allows us to have a
coherent picture that could be used in different studies as a
reference. To better understand the functional organization of
the network, we have reorganized the enzyme reactions into
about 70 pathways according to their functional relationships.
We further compared our network with other available human
networks such as HumanCyc (Romero et al, 2005) and the
recent reconstruction by Palsson’s group (Duarte et al, 2007).
A bow-tie connectivity structure is rediscovered from a
functional rather than structural point of view, and the
distribution of disease related metabolic reactions in the
bow-tie structure was investigated.
Reconstruction of the global network
The main processes for the reconstruction of the human
network are shown in Figure 1. The ﬁrst step is the
reconstruction of the network solely based on the human
gene annotation information. This network is called the
genome-based network. This step can be automated and thus
thegenome-basednetworkcanbeeasilyupdatedwiththenew
annotation information in the databases. Unfortunately, the
human gene contents in online databases are often very
different. For example, there are more than 38000 human
genes in the NCBI EntrezGene database (Maglott et al, 2007),
but only about 27 thousand in HGNC (Eyre et al, 2006).
Moreover, about 3000 genes in HGNC are not in EntrezGene.
Therefore, it is very important to integrate information from
differentdatabasestogetamorecompleteenzymegenelistfor
the reconstruction. In our reconstruction, we mainly obtained
the enzyme annotation from KEGG, Uniprot and HGNC.
Information from NCBI EntrezGene (Maglott et al, 2007),
Ensembl (Hubbard et al, 2007) and Genecard (Safran et al,
2002) databases are also included to provide more complete
crosslinks between gene (protein) IDs in different databases
and validate the enzyme gene annotation.
Special attention was paid on the genes with unclear EC
numbers such as 1.-.-.-. The existence of the unclear EC
numbers is because only a chemically well-characterized
enzyme is assigned an EC number by IUBMB. In the post-
genome era, this process is far behind the function annotation
of genes, which is mainly based on the DNA sequence. For
example, in the UniProt database there are more than 800
proteins annotated with an unclear EC numbers (Wu et al,
2006). For these geneswe could notget thereactions catalyzed
by its encoded enzymes through the EC numbers. The
reactions can only be added directly from the function
annotation part in Uniprot and many genes need to be
manually examined in literature.
Another problem in the reconstruction of the genome-based
network is the somehow ambiguous relationships between EC
numbers and reactions in the reaction databases. A protein in
human may not catalyze a reaction, which is catalyzed by a
protein with same EC number in other organisms. For example,
the GBA3 gene in human codes for cytosolic beta-glucosidase,
whichhaveanECnumber3.2.1.21,whereasinotherorganisms,
proteins with this EC number also function as cellobiase
catalyzing the degradation of cellulose. This degradation
reaction apparently does not occur in human. Unfortunately
there is still no automatic way to obtain the human-speciﬁc EC
number–reaction relationships. We ﬁrst used the KEGG ligand
database to generate the reaction list, because it is one of the
most complete metabolic reaction databases including more
than 7000 reactions (Goto et al, 2002). Then the reactions were
manually checked to exclude non-human reactions.
The second step of the reconstruction is to reﬁne the
genome-based network based on information from literature.
Fortunately, thanks to the EMP database (personal communi-
cation with EMP projects Inc.), we already have a literature
based human metabolic network available. The EMP network
is a compound centric network reconstructed mainly based on
information from literature. It contains more than a thousand
compounds and nearly 2000 reactions. We then can compare
and integrate the two networks together to obtain a more
GENOME-BASED METABOLIC NETWORK
  LITERATURE-BASED
METABOLIC NETWORK
A list of human metabolic
genes and EC numbers
from different databases
Clear EC numbers
A list of reactions
Compound and reaction matching
An integrated network
KEGG
ligand
Uniprot
literature
Unclear EC numbers
Human reactions
from EMP database
and literature
Figure 1 Processes for reconstruction of the high-quality human metabolic
network.
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ever, this integration process is very time consuming mainly
due to the different compound and reaction nomenclature
systems used in the two datasets. The reactions and
compounds in the genome-based network are mainly from
the KEGG ligand database, while EMP has its own nomen-
clature for reactions and compounds. In order to check if two
reactions from the two networks are the same, we need to
check if all the compounds in the reaction equations are the
same. A straightforward way to match the compounds in
different databases is to compare them by name. However,
even though both KEGG and EMP databases have a synonym
list for each compound, the total number of matching
compounds is only about 500 of the more than 2000
compounds in the two networks. This is a surprising result
consideringthatbotharehumanmetabolicnetworks.Wehave
tried different methods to obtain more compound matching
relationships such as using synonyms in other compound
databases such as PubChem (Wheeler et al, 2006) and ChEBI
(Brooksbank et al, 2005) to match the compounds in EMPand
KEGG, matching compounds by structure and allow fuzzy
matching between a generic compound and their speciﬁc
compounds (for example D-glucose and alpha D-glucose).
Unfortunately only about 300 new matching relationships
were obtained through these methods. Based on the matched
compounds, we found about 700 matching reactions between
the genome-based networkand the EMP network, bychecking
if two reactions have the same reactants. These matching
reactions allow us to compare the two networks at a higher
pathway level. If a pathway in EMP contains one or more
matching reactions with a KEGG pathway, then these two
pathwayswillbefunctionallylinked.Wecanthencomparethe
two pathways to see if they have some unfound matching
reactions or a reaction in one pathway complements a gap in
another pathway. This pathway consolidation process can
only be done by manual examination of the reactions in the
pathways and visual inspection of the pathway maps.
However, it is an important step to improve and maintain the
quality of the reconstructed network, and for us to better
understand the biological function of the large-scale network.
Pathway organization of the human
metabolic network
As described above, the pathway organization of reactions is
an important step in the network reconstruction. However, in
comparing the pathways in EMPand KEGG, we found they are
organized very differently. In EMP there are more than 300
metabolicpathwaysforthehumanmetabolicnetwork.Almost
100ofthemareverysmall,containingthreeorfewerreactions.
Moreover, in the pathway maps there is no link to other
pathways shown. Therefore, it is very difﬁcult to gain a whole
picture of the human metabolic network from so many small
pathways. In KEGG, all the reactions from different organisms
are organized into about a hundred metabolic pathways. The
problems with the KEGG pathways are the following: (1) it is
not human speciﬁc. In certain pathways only one or two
isolated human reactions exist; (2) there is a high overlap
between pathways. For example, there are many overlap
reactionsinthepathwaysofglutamatemetabolism,ureacycle,
arginine and proline metabolism. Grouping these pathways as
a big pathway would show the functional relationships
between the reactions in them much better; (3) the mass ﬂow
between a substrate and a product in the pathways is not as
clear as those in EMP or Biocyc (Karp et al, 2005). To address
these problems, we decided to deﬁne a new set of human-
speciﬁc pathways which are (1) human speciﬁc; (2) less
overlap between pathways; (3) large enough to include
functional related small pathways; (4) including links to other
pathway to get a better overview of functional connectivity
between pathways. Basically, the small pathways in EMP and
KEGG were grouped on the basis of their functional relation-
ships. Some original pathways may also be separated into
different new pathways. Altogether, 2823 reactions are
included in the network and reorganized into 66 pathways,
withthenumberofreactionsbetween5and142(therearealso
more than 300 isolated reactions in the network). The retinol
(vitaminA)pathwayisshowninFigure2asanexample.There
are much more reactions in our pathways than in the
corresponding KEGG pathways. More pathway maps and
the whole set of pathways in SBML format can be seen in the
Supplementary ﬁles (the Supplementary data set and Supple-
mentary ﬁgures, the network and the pathways in SBML
format are also available at http://wwwtest.bioinformatics.e-
d.ac.uk/wiki/PublicCSB/EHMN). The users can directly open
the SBML ﬁles in CellDesigner (Kitano et al, 2005) or other
softwarestogenerateanautomaticlayoutforthepathways.As
described in previous studies, the currency metabolites often
cause trouble in graph layout of metabolic pathways because
they tend to link all the metabolites in a short path. Therefore
in the SBML ﬁles for the pathways we include only the main
compounds in the‘listofreactants’and ‘listofproducts’section.
This makes it possible to quickly generate clear and nice
pathway maps from the SBML ﬁles.
In the process of pathway reorganizing, we noticed that
many reactions, especially those related with complex lipid
metabolism, are missing in the genome-based network, where
the reactions are mainly from KEGG ligand database. For
example,thereactionsrelatedwithomega-3andomega-6fatty
acid (two essential nutrients for human) metabolism, mono-
unsaturated fatty acid metabolism and epoxyeicosatrienoic
acids (EETs) metabolism are almost completely missing in
KEGG. Due to the great structural variance of complex lipids,
the total number of lipid metabolites is more than 8000 (Fahy
et al, 2005) and most of them exist in the human metabolic
network. Therefore, even though we already added many lipid
pathways from literature, the network is still far from
complete. A comprehensive database on lipids and their
relating enzymes in various organisms has been developed by
the LIPID MAPS Consortium (Fahy et al, 2005; Cotter et al,
2006). Based on information in this database and other
resources, more lipid-related pathways can be added in the
future version of our database.
We further compared our network with another computa-
tionally reconstructed network in HumanCyc (version 10.6)
(Romero et al, 2005). There are 996 reactions in the database,
and among them 766 are catalyzed by enzymes. This is only
half of the number of reactions in our database. We extracted
976 EC numbers from HumanCyc and compared them with
Human metabolic network reconstruction and analysis
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HumanCyc but not in our database. We then checked the
reactions and proteins corresponding to these EC numbers,
aiming to add new reactions to our database. Surprisingly, we
found that 116 of the 151 new EC numbers were without any
coding gene, but added by the pathway hole ﬁlling algorithm
used in Pathologic method for the computational reconstruc-
tion of metabolic networks in Biocyc (Karp et al, 2005).
However,manyofthemareinpathwayswheremanyreactions
are without any gene. For example, in the dTDP-L-rhamnose
biosynthesisI pathway, onlythe reaction catalyzedby4.2.1.46
is encoded by a human gene. The other three reactions
catalyzed by 1.1.1.133, 2.7.7.24 and 5.1.3.13 are all added to
complement the pathway. There is even no literature related
with these reactions in human. Therefore, we decided not to
include these reactions in our network. For the other 35 EC
numbers, we examined their corresponding genes and
checked how these genes are annotated in other databases
and literature. We found that 24 EC numbers unique in
HumanCyc are because of wrong annotation of the genes in
HumanCyc. For example, among the three genes encoding
2.4.1.87, gta actually functions as a galactosyltransferase
activator,CDC2L2isagalactosyltransferase-associatedprotein
kinase, ENSG00000165196 has already been removed in the
latest ENSEMBL database (Hubbard et al, 2007). For the other
10ECnumbers,fourhavenoreactionoraproteinmodiﬁcation
reaction, which is currently not included in our network.
Therefore, we only need to add reactions for six EC numbers
from HumanCyc. Actually some of the reactions are already in
our reconstruction, but with a different EC number. Altogether
nine reactions were added from HumanCyc. A complete list of
the manually examined EC numbers unique in HumanCyc can
be seen in Supplementary Table 1. The comparative analysis
between our network and HumanCyc indicates from one
aspect the importance of integrating information from
different databases for network reconstruction, and from
another side, the importance of human curation for improving
the quality of the computationally reconstructed network.
During the review processof the paper, another high-quality
human metabolic network reconstructed by Palsson’s group
(referredas HMN-Pbelow)waspublished (Duarte et al, 2007).
We obtained their data from the BiGG database and compared
with our network (EHMN). At the gene level, EHMN contains
2322 genes from different databases, HMN-P contains 1496
genes mainly from EntrezGene (actually all genes have
EntrezGene ID). The common part is 1069 genes. At enzyme
level, in HMN-P only less than half of the genes are assigned
EC numbers(total EC numbers less than 500including unclear
EC numbers). In EHMN, all the genes have clear or unclear EC
number because we start the reconstruction from such genes.
The total number of ECs is more than 800 (excluding unclear
ECs). One may argue that in HMN-P ECs are not used to link
genes with reactions. However, as a widely used standard for
representing metabolic reactions, introducing EC number in
the network can greatly simplify the comparative analysis of
metabolic networks for that the direct comparison of reaction
equations is very difﬁcult due to compound synonyms. At the
metabolite level, EHMN contains 2671 compounds, and 1769
of them can be found in KEGG database. HMN-P has 1469
compounds and about a half of them linked to KEGG. For the
non-KEGG compounds, in HMN-P only one compound name
isgiven.Thismakesitdifﬁculttoﬁndamatchingcompoundin
other databases. As stated previously, we have developed a
compound database with synonyms, structure information
and IDs in different databases (in Supplementary data set). At
thereactionlevel,HMN-Pcontains morereactions thanEHMN
(3731 versus 2823). However, there are 1189 transport
reactions and 457 exchange reactions, which are not con-
sidered in EHMN because the subcellular location information
is still not included. Furthermore, there are 290 repeat
reactions in HMN-P, which are the same reaction but in
different compartments. Therefore, the number of reactions
comparable with EHMN is just 1795. Because of the intrinsic
complexity of human cell, it is very difﬁcult to place the
reactions into a small number of compartments. Actually we
have collected protein location information from different
databases and have identiﬁed hundreds of cellular locations.
We are working on it to develop a GO (Gene Ontology)
(Ashburner et al, 2000)-based hierarchically compartmented
human network for the next release.
Functional analysis of the human
metabolic network and the bow-tie
structure
Unlike most microorganisms, which can use simple substrates
to produce all the metabolites required for its growth, human
requires many essential nutrients obtained directly from the
food to maintain a health physiological state. The typical
essential nutrients include 10 amino acids, omega-3 and
omega-6 fatty acids and various vitamins. To verify the
essentiality of these metabolites, we manually examined the
pathways related with them and found that there is no
pathwayfor thesynthesisofthese metabolitesfromthecentral
metabolites. For a more systematic analysis of the metabolic
capacity of the human metabolic network, we start from the
central metabolites (in glycolysis, pentose phosphate pathway
and TCA cycle pathway) and classify other metabolites as
exchangeable (pathways for both the synthesis from central
metabolites and the degradation to central metabolites exist),
degradable (only degradation pathways exist), synthesizable
(only synthesis pathways exist) and isolated (no pathway
from/to central metabolites) based on pathway analysis. We
found that many of the essential nutrients fall into the isolated
metabolites and some essential amino acids are degradable.
This metabolite classiﬁcation is quite similar with the bow-tie
structure of metabolic networks discovered previously based
on graph analysis (Ma and Zeng, 2003). In the bow-tie
structure, all the metabolites in the giant strong component
(GSC) can convert to each other (equal to the exchangeable
metabolites), the metabolites in the IN subset can convert to
metabolites in GSC (degradable), those in the OUTsubset can
be produced from metabolites in GSC (synthesizable) and
those in the isolated subset are not connected with GSC. Here
we rediscovery the bow-tie structure by functional analysis of
the metabolic network. Because graph is a simpliﬁed
representation of metabolic networks, which lose some
structure information (for example a multiple substrate
multiple product reaction just be represent as several links
Human metabolic network reconstruction and analysis
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found by graph analysis represents the true biological
organization principle of metabolic network is still an open
question. Here, based on a functional analysis of the high-
quality human metabolic network, we conﬁrmed the bow-tie
structure from a biological point of view. Due to the
simpliﬁcation in the graph conversion of a metabolic network,
the exact position of certain metabolites in the bow-tie may be
different for the two different approaches. However, as a
system level macroscopic structure, the bow-tie is true from
both structural and biological aspects. This fact strengthens
the hypothesis that bow-tie is an important organization
principle for complex systems to be robust and ﬂexible (Csete
and Doyle, 2004; Kitano, 2004).
Based on the classiﬁcation of the metabolites, the reactions
can also be classiﬁed into four subsets forming a bow-tie
structure similar to the bow-tie of the reaction graphs of
metabolic networks (Ma et al, 2004). The reactions occur
between the exchangeable metabolites are in the GSC. The
reactions in a pathway from the degradable metabolites to the
exchangeable metabolites form the IN subset. Correspond-
ingly, the reactions in a pathway from the exchangeable
metabolites to the synthesizable metabolites form the OUT
subset. All the other reactions are in the isolated subset. The
bow-tie classiﬁcation of the reactions is more interesting
because the reactions are linked to the genes and proteins,
which are the main functional regulation units in the cell. The
full classiﬁcation of the reactions can be seen in the
Supplementary ﬁle.
For the human network, we found that the scale of the
isolated subset is often very large (more than one fourth of the
whole network). We investigated the metabolites and reac-
tions in the isolated subsets and found that many of them are
actually not truly isolated, but can be produced from
metabolites in the IN subset and may have important
physiological function. As mentioned previously, human
requires many essential nutrients for growth. These nutrients
are essential because they are used for producing certain
metabolites with important physiological functions. For
example, the aromatic amino acids are precursors for
monoamine hormones and neuron transmitters. These signal
metabolites can bind to different protein receptors and then
regulate the amount and activity of proteins to change the
physiological state. Because many such signal molecules are
produced from essential nutrients, which are in the IN subset
ofthebow-tie,theyshouldbeintheisolatedsubsetofthebow-
tie structure. To distinguish these metabolites from the real
isolated metabolites, we generate a new subset called ‘OUT2’
to include the metabolites synthesized from the metabolites in
the ‘IN’ subset. Correspondingly, an ‘IN2’ subset, which
contains the metabolites for producing metabolites in ‘OUT’ is
also added. Therefore a six-subset modiﬁed bow-tie structure
of the human metabolic network is produced as shown in
Figure 3. The numbers of reactions in the six subsets are
shown in Table I.
A main objective of human metabolic network analysis is to
see how it is related with human disease. More than 10000
human genes (half of the whole genome) have been reported
to be related with one or more human diseases in the OMIM
database (Hamosh et al, 2005). In the human metabolic
network, we found that 2215 (of 2823) reactions are catalyzed
by enzymes, which are coded by disease related genes. If we
exclude the reactions, which are spontaneous or with an
unknown gene, the proportion of disease related reactions
is even higher at 95% (2215 of 2314 reactions with encoding
genes). This surprisingly high value raises a question
to us: what does network robustness really mean from a
biological aspect? As the most complex organism on the earth,
human is expected to have a very robust metabolic network.
Actually previous studies on biological network truly
suggest that as scale free networks, metabolic networks
are robust against random errors from a structural point of
view (Jeong et al, 2000). However, the result that most
reactions are linked with disease genes indicates that the
human metabolic network is fragile. We analyzed the
distribution of the disease related reactions in the bow-tie
structure and the result is shown in Table I. Interestingly
the proportion of disease-related reactions in the IN subset
Table I The bow-tie structure of human metabolic network and diseases
Subsets No. of reactions No. of reactions with encoding genes No. of disease-related reactions Percentage of disease-related reactions
Total 2823 2314 2215 95.72%
GSC 605 550 535 97.27%
IN 330 283 258 91.17%
OUT 984 788 777 98.60%
IN2 12 12 8 66.67%
OUT2 257 201 194 96.52%
Isolated 635 480 443 92.29%
Abbreviation: GSC, giant strong component.
IN GSC OUT
OUT2 IN2
IS
Figure 3 The bow-tie structure of the human metabolic network.
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reactions leading to metabolic products are more fragile
than the reactions for the degradation of various substrates.
This result looks unusual but understandable from biochem-
istry. The key function of the central pathways (glycolysis
and TCA cycle) is to produce energy and precursors for
biosynthesis. Most of the bioproducts can be synthesized
from a number of common metabolite precursors in the
central pathways, and most of the substrates are also
converted to these precursors ﬁrst for further conversion.
Therefore, theoretically one substrate is enough to produce
all the necessary products, if it can be converted to these
precursors. The existence of multiple pathways for multiple
substrates just provides more ﬂexibility to the organism
and thus blocking one pathway is unlikely to damage the
organism. In contrast, a product is synthesized in an organism
often because it has some unique function important for
the organism (as a structure molecule or a signal molecule).
Hence, a failure in a product synthesis pathway can make
the whole system organized improperly, causing a disease.
One step further, we may hypothesize that the organization
of the bio-products and their synthesis pathways from the
common precursors rather than the substrates and their
degradation pathways determine the feature of a biosystem.
Back to the bow-tie structure, the metabolites and
reactions in the Out subset may better deﬁne a biosystem
than the metabolites and reactions in the IN subset.
Further studies on comparative analysis of the metabolic
networks of different organisms are needed to validate this
hypothesis.
Supplementary information
Supplementary information is available at the Molecular
Systems Biology website (www.nature.com/msb) and the
EHMN website (wwwtest.bioinformatics.ed.ac.uk/wiki/
PublicCSB/EHMN).
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